Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 7,429 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Digestive System Neoplasms Clear all

Conditions: Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions: Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging; Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Rectal Cancer
Interventions: Bowel/rectal resection, non-operative follow up; Procedure · Other
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Pancreatic Cancer
Interventions: Tarceva (erlotinib HCl, OSI-774); Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 60
States / cities: Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 51 more

Conditions: Colorectal Cancer, Precancerous Condition
Interventions: cholecalciferol, placebo; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: encorafenib, Binimetinib, Cetuximab; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Germantown, Tennessee

Conditions: Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Prostate Cancer, Stage II Prostate Cancer, Stage I Prostate Cancer, Stage III Colorectal Cancer, Stage II Colorectal Cancer, Stage I Colorectal Cancer
Interventions: MINDSET, Enhanced Usual Care (EUC); Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: SNX281, pembrolizumab; Drug
Lead sponsor: Stingthera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 1 more

Conditions: Colon Cancer, Colorectal Cancer
Interventions: MRTX849, Irinotecan, Cetuximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: MRI/Imaging; Other
Lead sponsor: ClearNote Health; Industry
Eligibility: 50 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Scottsdale, Arizona • Atlantis, Florida • Greenville, South Carolina + 2 more

Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: Colon GVAX, cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Breast Cancer, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions: Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 159
States / cities: Jonesboro, Arkansas • Martinez, California • Augusta, Georgia + 134 more

Conditions: Pancreatic Cancer
Interventions: Fitbit Data Collection, Nutrition Counseling, Fact G Survey, General Anxiety Disorder (GAD)-7, Patient Health Questionnaire (PHQ)-9; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Colorectal Polyp, Colorectal Adenoma, Colon Cancer
Interventions: Endocuff Vision; Device
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Progressive Metastatic Malignancies
Interventions: ALT-801; Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more

Conditions: Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions: MAGNET; Device
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Solid Tumor, Lymphoma
Interventions: Ad-p53; Drug
Lead sponsor: MultiVir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Morristown, New Jersey

Conditions: Colorectal Neoplasms
Interventions: MEDI6469; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Cancer
Interventions: MM-141, Placebo, Gemcitabine, Nab-Paclitaxel; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 47
States / cities: Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more

Conditions: Colorectal Cancer
Interventions: FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, semaxanib; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Zanzalintinib; Procedure · Drug
Lead sponsor: Devalingam Mahalingam; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Visceral Pain, Pancreatic Cancer
Interventions: Transcranial Magnetic Stimulation; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular
Interventions: IDN-6556, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more

Conditions: Adenomatous Polyposis Coli
Interventions: Erlotinib, Sulindac, Placebo A, Placebo B; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 69 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy

Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer

Standard Colonoscopy Versus Colonoscopy With Endocuff Vision

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

TMS for the Treatment of Pancreatic Cancer Pain

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients